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Abstract
The amyloid precursor protein/presenilin 1 (APP/PS1) mouse model of Alzheimer’s disease (AD) has
provided robust neuropathological hallmarks of familial AD-like pattern at early ages, whereas
senescence-accelerated mouse prone 8 (SAMP8) has a remarkable early senescence phenotype with
pathological similarities to AD. The aim of this study was the investigation and characterization of
cognitive and neuropathological AD markers in a novel mouse model that combines the characteristics
of the APP/PS1 transgenic mouse model with a senescence-accelerated background of SAMP8 mice.
Initially, significant differences were found regarding amyloid plaque formation and cognitive
abnormalities. Bearing these facts in mind, we determined a general characterization of the main AD
brain molecular markers, such as alterations in amyloid pathway, neuroinflammation, and
hyperphosphorylation of tau in these mice along their lifetimes. Results from this analysis revealed that
APP/PS1 in SAMP8 background mice showed alterations in the pathways studied in comparison with
SAMP8 and APP/PS1, demonstrating that a senescence-accelerated background exacerbated the
amyloid pathology and maintained the cognitive dysfunction present in APP/PS1 mice. Changes in tau
pathology, including the activity of cyclin-dependent kinase 5 (CDK5) and glycogen synthase kinase 3
β (GSK3β), differs, but not in a parallel manner, with amyloid disturbances.
Keywords: Familial Alzheimer’s disease (fAD), Aging, β-Amyloid, Tau hyperphosphorylation,
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Introduction
Aging-associated processes, neurodegenerative diseases the most prevalent of these, result mainly from
the deleterious effects of time on cellular mechanisms (Smith et al. 1996; Agarwal et al. 2003). The
main neurodegenerative diseases are Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD), and
amyotrophic lateral sclerosis (ALS) (Zhu et al. 2004, 2007), with AD being the most prevalent and one
of the most studied of these and characterized by mild cognitive impairment, deficits in short-term
# #
#
memory, spatial memory loss, and subtle emotional imbalances (Enserink 1998), and ultimately causing
death (Pimplikar 2009).
With regard to histopathology, changes in AD brains include neuronal and synaptic loss and the
appearance of two basic hallmarks: senile plaque (SP) formation by accumulation of extracellular of
β-amyloid protein (Aβ) (Glenner and Wong 1984; Braak and Braak 1991, 1998), and intracellular
neurofibrillary tangles (NFT) formation by accumulation of hyperphosphorylated tau protein (Bancher
et al. 1989; Braak and Braak 1995).
Over time, AD could be divided into two clinical phases, depending on the age of onset (Koedam et al.
2010). On the one hand, it is possible to find a familial Alzheimer’s disease (fAD), which was usually
defined for individuals <65 years of age, accounting for 5 % of all cases (Harvey 2003) and directly
linked with highly penetrant autosomal dominant mutations in one of three different genes: the
presenilin 1 (PS1) gene, the presenilin 2 (PS2) gene, or the amyloid precursor protein (APP) gene
(Campion et al. 1999). On the other hand, it is possible to find sporadic Alzheimer’s disease (sAD),
which accounts for approximately 95 % of all AD cases and which likely results from the complex
interplay of molecular, environmental, and genetic factors (Guimerà et al. 2002; Koedam et al. 2010;
Feng and Wang 2012).
Due to the high degree of variability and its scattered etiology, many problems have had to be overcome
in the last two decades of research on aging and associated neurodegenerative diseases. The models
usually used are mice that are genetically modified by human gene insertions with the main proteins
associated with AD (APP, PS1, PS2, and tau) or tau kinase overexpression (cyclin-dependent kinase 5
[CDK5] or glycogen synthase kinase 3 β [GSK3β]) (Lucas et al. 2001; Piedrahita et al. 2010). However,
none of the numerous animal models reliably reflect what occurs in humans because AD should be
considered a polyetiologic disease (Itzhaki 1994) that is caused by disruption of a wide range of
molecular mechanisms. At the same time, it should be borne in mind that the mutations introduced into
transgenic models are related with mutations linked with fAD cases; thus, animal models will not be
representative of the vast majority of cases of the sporadic type of Alzheimer’s disease (Guimerà et al.
2002; Koedam et al. 2010; Feng and Wang 2012).
It is noteworthy that advanced age is the most important risk factor for the development of sAD
(Wisniewski et al. 1996). It was thought that acquiring a more representative model of the sAD type
will thus lead to a better understanding of the relationship among changes in homeostasis in senescence
and AD, and at this stage, Lok et al. (2013a, b) presented a combined model of AD (amyloid precursor
protein/presenilin 1 (APP/PS1)) with senescence-accelerated mouse prone 8 (SAMP8), a representative
model of aging, to obtain a new model that displays the characteristics of both.
On the other hand, we decided to use the double transgenic APP/PS1 mice as an animal model of AD,
which can contribute cerebral pathologic changes similar to those in humans and which can be used to
simulate neuropathologic changes such as SP formation, neuroglial cell proliferation, and decrease of
synapses and dendrites (Irizarry et al. 1997; Games et al. 2006; Codita et al. 2006). APP/PS1 mice
express a chimeric mouse/human APP bearing the Swedish mutation (Mo/HuAPP695swe) (Borchelt et
al. 1996; Dewachter et al. 2000), exhibiting a marked elevation in Aβ protein level and Aβ deposition in
the cerebral cortex and hippocampus and developing similar neuropathological hallmarks to those
observed in AD brains (Games et al. 1995), and a mutant human PS1-ΔE9 (Borchelt et al. 1996;
Campion et al. 1999) that displays an increased Aβ42 peptide formation, potentiating amyloid
deposition through superactivation of the PS1 catalytic form (McGowan et al. 1999).
SAMP8 is characterized by deficits in learning and memory (Takeda et al. 1981; Miyamoto et al. 1986;
Takeda 2009), emotional disorders such as reduced anxiety-like behavior (Miyamoto et al. 1992;
Markowska et al. 1998), impaired immune response, etc. (Yagi et al. 1988; Flood and Morley 1998) at
an earlier age. More importantly, this strain is increasingly being recognized as a model of age-related
AD (Pallas et al. 2008; Morley et al. 2012) because it shows an AD-related pathology with aging such
as alterations in APP processing by secretases (Morley et al. 2000, 2002), increases in Aβ (Del Valle et
al. 2010) and in other protein aggregates (Manich et al. 2011), cerebral amyloid angiopathy (del Valle et
Go to:
al. 2011), and increases in tau hyperphosphorylation (Canudas et al. 2005).
Thus, the goal of the present work is to examine key biochemical and functional characteristics of this
disease, including the study of memory impairment, and amyloid and tau pathologies, combining the
features of the accelerated senescence background of SAMP8 mice and the APPswe/PS1-ΔE9
mutations of APP/PS1 mice, and this mouse was APP/PS1/SAMP8 and denominated as SHAP.
Materials and methods
Animals
SAMP8 and APP/PS1 mouse strains were commercially available (Harlan Laboratories). The
generation of APP/PS1 mice expressing human mutated forms of APP and PS1-ΔE9 has already been
described (Borchelt et al. 1996). New model strains, SHAP(+) and SHAP(−), were obtained through
crossing the male APP/PS1 (n = 5) and the female SAMP8 (n = 13). All mice have been backcrossed to
their parental strain for at least five generations, and once the progeny was obtained (n = 92), the
animals were genotyped by conventional polymerase chain reaction (PCR), following the protocol
proposed by Jackson Laboratory for APP/PS1, resulting in 57.6 % SHAP(+) (n = 53), with both
transgenes, and 42.4 % SHAP(−) (n = 39), without any transgene.
Experimental procedures were carried out with the following four mice strain groups at 3, 6, 9, and
12 months (12 experimental groups): SAMP8 (n = 12, three for each age), APP/PS1 (n = 16, four for
each age), SHAP(+) (n = 16, four for each age), and SHAP(−) (n = 12, three for each age).
All of the animals were fed a standard chow (2018 Teklad Global 18 % Protein Rodent Maintenance
Diet, Harlan) and water ad libitum and were maintained under standard temperature conditions (22 ±
2 °C) of 12-h light/12-h dark cycles (300 lx/0 lx) and at a relative humidity of 55 %. Studies were
performed in accordance with the institutional guidelines for the care and use of laboratory animals
(European Communities Council Directive 86/609/EEC) established by the Ethical Committee for
Animal Experimentation at the University of Barcelona.
Object recognition test
Nine- and 12-month-old SAMP8, APP/PS1, SHAP(+), and SHAP(−) animals were placed in a 90°,
two-arm, 25-cm-long, 20-cm-high, and 5-cm-wide black maze. Light intensity in the middle of the field
was 30 lx. The objects to be discriminated were made of plastic (object A, 5.25 cm in height, and object
B, 4.75 cm in height). For the first 3 days, the mice were individually acclimatized to the apparatus for
10 min. On day 4, the animals were submitted to a 10-min acquisition trial (first trial), during which
they were placed in the maze in the presence of two identical novel objects (A + A or B + B), which
were localized at the end of each arm. A 10-min retention trial (second trial) occurred 2 h later. During
this second trial, objects A and B were placed in the maze, and the time that the animal explored the
new object (t ) and the old object (t ) was recorded, and an object discrimination index (DI) was
calculated by comparing the exploration time of the familiar and the novel objects during the test,
defined as (t − t )/(t + t ). Understanding as exploration of an object was directing the nose at a
distance ≥2 cm to the object and/or touching it with the nose, while turning around or sitting on the
object was not considered as an exploration (Antunes and Biala 2012). In this case, as well as in most
studies, exploration was defined as the orientation of the animal’s snout toward the object, sniffing or
touching with the snout, while running around the object and sitting or climbing on it was not recorded
as exploration (Bahrick et al. 1997; Aubele et al. 2008). In order to avoid object preference biases,
objects A and B were counterbalanced so that one half of the animals in each experimental group were
first exposed to object A and then to object B, whereas the other one half saw first object B and then
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Animals were anesthetized with 80 mg/kg of sodium pentobarbital and intracardially perfused with
saline serum. Afterward, brains were dissected and separated sagitally in two hemispheres: one for
immunohistochemistry and the other for protein extraction. Immunohistochemistry brains were frozen
by immersion in isopentane, chilled on dry ice, and stored at −80 °C until sectioning. Thereafter, frozen
brains were embedded in OCT cryostat-embedding compound (Tissue-Tek, Torrance, CA, USA), cut
into 20-μm-thick sections on a cryostat (Leica Microsystems, Germany) at −18 °C, and placed on slides.
Slides containing brain sections were fixed with acetone for 10 min at 4 °C, allowed to dry at room
temperature, and then frozen at −20 °C until further staining. The remaining hemispheres were
dissected in total cortex and total hippocampus and stored at −80 °C until protein extraction and Aβ
quantification.
Thioflavin S staining
Slides were allowed to defreeze at room temperature and then were rehydrated with phosphate-buffered
saline (PBS) for 5 min. Later, the brain sections were incubated with 0.3 % thioflavin S (Sigma-
Aldrich) for 20 min at room temperature in the dark. Subsequently, these were submitted to washes in
3-min series, specifically with 80 % ethanol (two washes), 90 % ethanol (one wash), and three washes
with PBS. Finally, the slides were mounted using Fluoromount (EMS), allowed to dry overnight at
room temperature in the dark, and stored at 4 °C. Image acquisition was performed with an
epifluorescence microscope (BX41; Olympus, Germany). For plaque quantification, similar and
comparable histological areas were selected, focusing on having the hippocampus and the whole
cortical area positioned adjacently.
Quantification of soluble β-amyloid
Frozen samples of the cortex and hippocampus of SHAP(+), SHAP(−), APP/PS1, and SAMP8 mice
aged 3, 6, 9, and 12 months were wet mass determined (120 mg) and homogenized in ice-cold
guanidine buffer (5 M guanidine hydrochloride/50 mM Tris-Cl, pH 8.0). The detection and
measurement of β-amyloid 1-40 and β-amyloid 1-42 was carried out by enzyme-linked
immunoabsorbent assay (ELISA) with the corresponding detection kits (Invitrogen, Carlsbad, CA,
USA), following the instructions of the supplier and after optimizing the reaction with increasing
amounts of known concentrations of β-amyloid 1-40 and β-amyloid 1-42.
Immunohistochemistry
Slides were allowed to defreeze at room temperature and then rehydrated with PBS for 5 min. Then,
brain sections were blocked and permeabilized with PBS containing 1 % bovine serum albumin (BSA;
Sigma-Aldrich) and 0.1 % Triton X-100 (Sigma-Aldrich) for 20 min. After two, 5-min washes in PBS,
the slides were incubated with the primary antibody for Iba-1 (WAKO, 1:500) and glial fibrillary acidic
protein (GFAP, Abcam, 1:500) (see Table 1) overnight at 4 °C. They were then washed again and
incubated for 1 h at room temperature in the dark with Alexa Fluor secondary antibody. Finally, the
slides were washed, mounted using Fluoromount (EMS), allowed to dry overnight at room temperature,
and stored at 4 °C. Image acquisition was performed with an epifluorescence microscope (BX41,
Olympus, Germany).
Table 1
List of antibodies used
Primary antibody Host Source Catalog Work dilution
IHC WB
APP C-terminal Mouse Covance SIG-39152 1:1000
Primary antibody Host Source Catalog Work dilution
IHC WB
BACE1 Rabbit Millipore AB5832 1:500
CDK5 Rabbit Santa Cruz Biotech sc-173 1:1000
ERK-1/2 Rabbit Cell Signaling #9102 1:1000
GSK3β Rabbit Cell Signaling #9315 1:1000
p35/p25 Rabbit Cell Signaling #2680 1:1000
Phospho-Tau Ser199 Rabbit Invitrogen 44734G 1:1000
Phospho-Tau Tyr205 Rabbit Invitrogen 44738G 1:1000
Phospho-Tau Ser396 Rabbit Invitrogen 44752G 1:1000
Phospho-Tau Ser404 Rabbit Invitrogen 44758G 1:1000
Phospho-ERK-1/2 (Thr202/Tyr204) Rabbit Cell Signaling #9101 1:1000
Phospho-GSK3β (P-Tyr216) Rabbit Abcam ab75745 1:1000
Phospho-SapK/JNK (Thr183/Tyr185) Mouse Cell Signaling #9255 1:2000
Presenilin 1 Rabbit Calbiochem 529592 1:1000
SapK/JNK Rabbit Cell Signaling #9252 1:1000
Total tau Mouse Abcam ab39524 1:500
β-Actin Mouse Sigma-Aldrich A5441 1:20,000
Alexa Fluor 488 donkey anti-mouse IgG A 1:50
Alexa Fluor 546 donkey anti-rabbit IgG A 1:50
Iba-1 Rabbit Wako Chemicals 019-19741 1:250
GFAP Mouse Abcam ab10062 1:250
Open in a separate window
IHC immunohistochemistry, WB Western blot
Protein extraction
Brains were micronized by freezing with liquid nitrogen and grinding with a mortar. For total protein
extraction, lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1 % Triton X-100, pH 7.4),
EDTA-free protease inhibitor cocktail (Roche, Mannheim, Germany), and phosphatase inhibitor
cocktail 1 (Sigma-Aldrich, St. Louis, MO, USA) were added to the micronized tissue and left on ice for
30 min. Then, the samples were centrifuged at 10,000 × g for 10 min and a supernatant with total
protein content was collected. All of the protein extraction steps were carried out at 4 °C. Protein
concentration was determined by the Bradford protein assay.
Western blot
For Western blot analysis, 20 μg of protein was denatured at 95 °C for 5 min in sample buffer (0.5 M
Tris-HCl, pH 6.8, 10 % glycerol, 2 % sodium dodecyl sulfate (SDS), 5 % β-mercaptoethanol, 0.05 %
bromophenol blue), separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) onto 8–12 % polyacrylamide gels and transferred onto Immobilon polyvinylidene
difluoride membranes (Millipore, Billerica, MA, USA). The membranes were incubated overnight at
4 °C with the primary antibodies (see Table 1) diluted with Tris-buffered saline containing 0.1 % Tween
20 (TBS-T) and 5 % BSA. Membranes were then washed and incubated with secondary antibodies (see
Table 1) and diluted with TBS-T for 1 h at room temperature. Protein bands were visualized using a
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chemiluminescent HRP substrate (Millipore) and ChemiDoc XRS+ (Bio-Rad). Band intensities were
quantified by densitometric analysis using Image Lab software and values were normalized to β-actin,
except for C-terminal fragments (CTF) of APP (14 kDa), also named C99, which were normalized by
APP protein and phospho-tau protein levels, which were normalized by total tau protein.
Statistical analysis
Results were analyzed statistically by SPSS 19.0 (SPSS Inc., Chicago, IL, USA) software and
GraphPad PRISM (GraphPad Software, Inc.) software. Data are presented as mean ± standard error of
the mean (SEM), and means were compared with two-tailed, unpaired Student t test or one-way
analysis of variance (ANOVA) followed by Tukey’s multiple comparison test when necessary. In the
ORT, a one-sample t test was used to examine whether single columns were different from zero.
Statistical significance was attained when p values were <0.05.
Results
SHAP mice characteristics across aging
Throughout the study, animal weight monitoring was conducted weekly. From the results (Fig. 1), it can
be observed that at early ages, weights of the novel mice obtained did not show significant weight
differences among themselves but did in comparison with parental strains APP/PS1 and SAMP8. When
age and differences among strains were maintained and weight gain patterns were similar in SHAP and
APP/PS1 model, increasing over time, in turn and as expected, SAMP8 presented a very weak growth,
with significantly lower weight than other experimental groups.
Fig. 1
Body weight (BW, in grams [g]) of the studied models in function of age (months). Analysis of variance
(ANOVA) following Tukey’s multiple comparison test: **p < 0.01 vs. SAMP8; p < 0.01 vs. amyloid
precursor protein/presenilin 1 (APP/PS1)
Object recognition test
At late age (9 and 12 months), ORT demonstrated that SAMP8, APP/PS1, and SHAP(+) mice showed
impaired memory, while SHAP(−) did not (Fig. 2). To date, it has been found that transgenic mice with
$$
SHAP(+) maintain loss of memory, but preservation of memory in comparison with SAMP8 occurs
when transgenes are not present in SHAP(−) mice.
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Fig. 2
Discrimination index (DI) of different groups of senescence-accelerated mouse prone 8 (SAMP8) animals
at 9 and 12 months of age. Bars represent mean ± standard error of the mean (SEM). Analysis of variance
(ANOVA) following Tukey’s multiple comparison test: one-sample t test—*p < 0.05 vs. SAMP8; p <




Plaque histopathologic state was analyzed in all experimental groups and at each age through thioflavin
S staining. No SP were determined in any mouse strains at 3 months (data not shown), as described
previously for APP/PS1 and SAMP8 mice (Butterfield and Poon 2005; Aso et al. 2012). Strains
expressing APP and PS1 transgenes showed a burden of Aβ depositions that increased with age (Fig. 
3g–l), whereas SAMP8 and SHAP(−) strains, both without transgene, did not (Fig. 3a–f). Specifically,
APP/PS1 showed early deposition at 6 months (Fig. 3j), always exhibiting higher levels of Aβ
deposition in the cortex than in hippocampus areas (Fig. 4). Conversely, SHAP(+) mice demonstrated a
delayed initial deposition time. At 9 months, SHAP(+) presented SP (Fig. 3h) and displayed higher
levels in comparison with APP/PS1 at this age (Figs. 3k and 4a). At 12 months, SHAP(+) showed
increased levels of burden Aβ deposition in all studied areas (Figs. 3i–l and 4a), in comparison with
APP/PS1 (Figs. 3l and 4l). We found significant higher soluble Aβ-40/42 levels in both transgenic
strains in reference to SAMP8 and SHAP(−) (Fig. 4b, c). Increasing quantities of soluble Aβ-42 were
determined in SHAP(+) in front of APP/PS1, only at 3-months old.
Open in a separate window
Fig. 3
Thioflavin S staining of β-amyloid plaques in mouse brains. Representative images of histopathological
brain state of senescence-accelerated mouse prone 8 (SAMP8) (a–c), SHAP(+) (d–f), SHAP(−) (g–i), and
amyloid precursor protein/presenilin 1 (APP/PS1) (j–l) at different times in life (6, 9, and 12 months).
White arrows are representative indicators of the presence of β-amyloid plaques in the areas studied:
cortex (Cx) and hippocampus (Hp)
Open in a separate window
Fig. 4
a Quantification of number of β-amyloid plaques at 6, 9, and 12 months of age in the cerebral cortex (Cx)
and hippocampus (Hp) of amyloid precursor protein/presenilin 1 (APP/PS1) and SHAP(+). b Levels of
soluble Aβ-40 and Aβ-42, respectively, at 3, 6, 9, and 12 months. For quantification parameters, see
“Materials and methods.” Bars represent mean ± standard error of the mean (SEM). Analysis of variance
(ANOVA) following Tukey’s multiple comparison test: ***p < 0.001 vs. SAMP8 and SHAP(−); p <
0.05, p < 0.01, p < 0.001 vs. APP/PS1, p < 0.001
Gliosis, linked with SP formation, was assessed by GFAP immunohistochemistry at the final stage
(12 months). Results showed astroglial activation in APP/PS1 (Fig. 5n, p) and SHAP(+) (Fig. 5j, l) but
not in SAMP8 (Fig. 5b, d) and SHAP(−) (Fig. 5f, h). Double staining with thioflavin S and GFAP
demonstrated the colocalization of astroglial reactivity with β-amyloid deposition in APP/PS1 and
SHAP(+), confirming that glial activation is related with the presence of amyloid protein aggregates
both in cortical (Fig. 5j, n) and hippocampal areas (Fig. 5l and p). Conversely, when microglial
activation was determined by Iba-1 immunohistochemistry, mice with APP/PS1 double transgene,
SHAP(+), and APP/PS1 exhibited some degree of microglial activation in cortical regions (Fig. 
5i and m) and the hippocampus (Fig. 5k and o).
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Fig. 5
Immunohistochemical (cortex and hippocampus) staining of Iba-1 (green) and GFAP (red).
Representative images of glial state of senescence-accelerated mouse prone 8 (SAMP8) (a–d), SHAP(+)
(i–l), SHAP(−) (e–h), and amyloid precursor protein/presenilin 1 (APP/PS1) (m–p) mice at 12 months of
age. Yellow arrows are representative indicators of microglial activation in studied areas, whereas white
arrows are representative indicators of β-amyloid plaques and glial fibrillary acidic protein (GFAP)
staining. Scale bar for Iba-1 images is 100 μm, for GFAP + Tio-S 200 μm
Amyloid pathology in the APP/PS1/SAMP8
On observing changes in β-amyloid deposition in the newly generated strain, we decided to assess the
effect of age on the level of β-secretase (BACE1), PS1, and known intermediates and end products of
APP processing.
Highest levels in BACE1 were found in SAMP8 and in newly generated mice SHAP(+) and SHAP(−)
in reference to APP/PS1 at up to 9 months (Fig. 6). In contrast, at 12 months, APP/PS1 achieved the
highest levels of BACE1 compared with SAMP8 and SHAP mice (Fig. 6). An increase in 48 kDa
fragment, corresponding to the catalytic core of PS1, was detected only in SHAP(+) at the oldest age
tested (12 months) (Fig. 7). In reference to the proteolytic fragment (18 kDa) of constitutive PS1, we
determined a higher level in SAMP8 in reference to mice carrying the human PS1 mutation, APP/PS1,
and SHAP(+) according to the nature of this mutation (Fig. 6), which do not require cleavage activation
of PS1, being constitutively active. Surprisingly, APP/PS1 exhibited an increase in this fragment at
12 months, indicating possible endoproteolysis of the endogenous murine PS1 isoform.
Fig. 6
Levels of BACE of senescence-accelerated mouse prone 8 (SAMP8), SHAP(−), SHAP(+), and amyloid
precursor protein/presenilin 1 (APP/PS1). Bars represent mean ± standard error of the mean (SEM);
values are adjusted to 100 % for levels of SAMP8. Analysis of variance (ANOVA) following Tukey’s
multiple comparison test: *p < 0.05, **p < 0.01 vs. SAMP8; p < 0.05, p < 0.01 vs. APP/PS1; p <
0.05 vs. SHAP(−)
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Fig. 7
Levels of presenilin 1 (PS1), holoprotein (48 kDa), and CTF fragment (18 kDa) of senescence-
accelerated mouse prone 8 (SAMP8), SHAP(−), SHAP(+), and amyloid precursor protein/presenilin 1
(APP/PS1) mice. Bars represent mean ± standard error of the mean (SEM); values are adjusted to 100 %
for levels of SAMP8. Analysis of variance (ANOVA) following Tukey’s multiple comparison test: **p <
0.01 vs. SAMP8; p < 0.05, p < 0.01 vs. APP/PS1; p < 0.05, p < 0.01 vs. SHAP(−)$ $$ # ##
Levels of APP and C99 fragment were significantly increased in SHAP(+) and APP/PS1 in comparison
with SHAP(−) and SAMP8 mice aged 3 and 6 months, respectively (Fig. 8). These facts are in
agreement with the presence of the APP transgene and higher Aβ deposition in these mice but not in
SHAP(−) and SAMP8.
Open in a separate window
Fig. 8
Western blot analysis for amyloid precursor protein (APP) of senescence-accelerated mouse prone 8
(SAMP8), SHAP(−), SHAP(+), and APP/presenilin 1 (PS1) mice. Upper panels present the analysis of
full APP levels at the studied ages. Lower panels present C-terminal beta fragment (CTFß/APP ratio).
Bars represent mean ± standard error of the mean (SEM); values are adjusted to 100 % for levels of
SAMP8. Analysis of variance (ANOVA) following Tukey’s multiple comparison test: *p < 0.05, **p <
0.01 vs. SAMP8; p < 0.05, p < 0.01 vs. APP/PS1; p < 0.05, p < 0.01 vs. SHAP(−)
Characterization in tau pathology
Different tau phosphoepitopes were studied, including Tau Ser199, Tau Tyr205, Tau Ser396, and Tau
Ser404. Along the aging process studied in this novel strain, no changes were observed in the levels of
the different phospho-tau studied, which presented high variability in the levels of each epitopes
studied, except for APP/PS1 at the oldest age tested, where we observed higher levels of phospho-tau in
comparison to SAMP8 (Fig. 9). In addition, we studied total tau levels along the aging process, and it
did not show significant changes in these levels (data not shown).
Fig. 9
Levels of phosphorylated Tau at Ser199, Tyr205, Ser396, and Ser404 epitopes. Bars represent mean ±
standard error of the mean (SEM) and values are adjusted to 100 % for levels of senescence-accelerated
mouse prone 8 (SAMP8) mice. Analysis of variance (ANOVA) following Tukey’s multiple comparison
test: *p < 0.05, **p < 0.01 vs. SAMP8; p < 0.01 vs. APP/PS1; p < 0.05, p < 0.01 vs. SHAP(−)
$ $$ # ##
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GSK3β (phospho-Tyr279) levels, the active forms of these tau kinases, were higher in SHAP(+) than in
APP/PS1 and SAMP8 (Fig. 10). At the same time, higher levels of CDK5 were determined in SHAP(+)
at 12 months in comparison with SAMP8 and APP/PS1, concurrently with an increase in the coactivator
p25, indicating a possible enhanced process of phosphorylation in these animals (Figs. 9 and 10). Also,
phospho-SapK/c-Jun N-terminal kinase (JNK) was raised in SHAP(+) in comparison with reference to
SAMP8 and APP/PS1 (Fig. 10).
Fig. 10
Levels of CDK5, p25, GSK3β, and SAPK/JNK. Bars represent mean ± standard error of the mean (SEM)
and values are adjusted to 100 % for levels of senescence-accelerated mouse prone 8 (SAMP8) mice.
Analysis of variance (ANOVA) following Tukey’s multiple comparison test: *p < 0.05, **p < 0.01 vs.
senescence-accelerated mouse prone 8 (SAMP8); p < 0.05, p < 0.01 vs. amyloid precursor
protein/presenilin 1 (APP/PS1); p < 0.05, p < 0.01 vs. SHAP(−)
Oxidative enzymatic machinery
Levels of SOD1, catalase, and iNOS were determined by Western blot to detect changes in the oxidative
machinery in the new generated strain, that is SHAP(+). Results showed no changes in any of the
enzymes linked with oxidative stress (OS) (data not shown).
Discussion
Current mouse models of AD are restricted to the expression of AD-related pathology associated with
specific mutations present in early-onset fAD, thus representing <5 % of AD cases. To date, there are no
mouse lines that model continuum development and late-onset/age-related AD, which accounts for the
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vast majority; therefore, the chronology of events that lead to the disease in the aged population is
difficult to establish based on current animal models. Moreover, published data show that SAMP8, a
model of accelerated aging, displays many features in the brain that are known to occur in AD (i.e.,
increased OS, Aβ alterations, and tau hyperphosphorylation) (Takeda 2009; Morley et al. 2012).
Therefore, SAMP8 mice may offer an excellent model for studying the earliest neurodegenerative
changes associated with AD and provide a more encompassing picture of the disease, considering AD
as a syndrome triggered by a combination of age-related events. On the other hand, APP/PS1 are double
transgenic mice that express a chimeric mouse/human amyloid precursor protein (Mo/HuAPP695swe)
and a mutant human presenilin 1 (PS1-ΔE9). The presence of amyloid burden in the cortex and
hippocampus (CA3 and CA1) were demonstrated in APP/PS1 transgenic mice available at our
laboratory (Aso et al. 2012). To date, the leading hypothesis, the Aβ hypothesis, which is based on
mutations in either APP or PS1/2 that affect the processing of APP and contribute to Aβ accumulation
in neurons and to the consequent formation of senile plaques (Perry et al. 2000), has come under
increased scrutiny. In fact, it is becoming increasingly discussed that Aβ deposition could be a
consequence, rather than an initiator, of the pathophysiological cascade (Swomley et al. 2013). Other
mechanisms of the disease, such as abnormally hyperphosphorylated bundles of tau protein found in
neurofibrillary tangles, oxidative stress, metal ion deregulation, inflammation, and age, must be taken
into account in order to delineate the complete picture of the disease (Verri et al. 2012; Swomley et al.
2013).
Recently, Lok et al. (2013a, b) crossed APP/PS1 mice with the SAMP8 generating a new AD mouse
model, expressing human APP/PS1 genes on a senescence background, covering a phenotypical
analysis by studying working memory, spatial memory, motor performance, and anxiety-like behavior,
as well as changes in neuronal cell death and amyloid deposition. We applied the same strategy in the
present work, crossing APP/PS1 with SAMP8, delivering a double transgenic mouse in SAMP8
background, named SHAP(+). The goal was to better characterize at the biochemical and molecular
levels in this mouse with neuropathological traits of human AD in a senescence environment. Both
short- and long-term memory deficits are hallmarks of AD. While long-term memory impairment
appears only when the disease is in advanced stages and usually already diagnosed, early stages of the
disease are characterized by short-term memory deficits (Grady 2001) and they have been widely used
as an indicator of AD onset. Thus, only short-term memory deficits were assessed in this study, showing
that SHAP(+) had similar memory disturbances to those of SAMP8 and APP/PS1 at old ages, in
accordance with impairment in spatial memory or working memory reported earlier (Lok et al. 2013a,
b). Short-term memory loss was accompanied by a significant increase in SP, these being the highest at
12 months of age compared with SAMP8 and APP/PS1.
The Swedish mutations (K595N/M596L) included increased the amount of Aβ produced by favoring
the processing through the secretase pathway. Levels of APP were higher in SHAP(+) in mice aged up
to 9 months old, probably related with SAMP8 strain (Kumar et al. 2009), but at 12 months, these were
lower than in APP/PS1, probably due to higher cleavage to the amyloid peptides that accumulate in the
plaques that, as previously mentioned, were significantly increased at this stage. Analysis of BACE1, a
β-secretase, revealed that there were sparse and no consistent changes in SHAP(+) in comparison to
SAMP8. In SAMP8 and SHAP(−), where the transgenic mutant human presenilin protein (PS1-ΔE9)
and human APP were not expressed, there were no amyloid depositions; therefore, the expression of
human PS1 and APP in APP/PS1 in SHAP(+) is the key factor for amyloid accumulation in these two
strains, to a greater degree than the presence and levels of BACE1.
In reference to PS1 function, it is known that uncleaved PS1 holoprotein (full-length PS) (48–52 kDa) is
an inactive zymogene that must be activated by endoproteolytic cleavage (Li et al. 2000; Fukumori et
al. 2010). There is compelling evidence that full-length PS1 is subject to endoproteolytic processing,
generating N-terminal (NTF) (27–28 kDa) and CTF (16–18 kDa) (Thinakaran et al. 1996; Chávez-
Gutiérrez et al. 2008). Once PS1 is cleaved, NTF (27–28 kDa) and CTF (16–18 kDa) form a
biologically active NTF-CTF heterodimer, and the γ-secretase substrate can reach the catalytic site
(Chávez-Gutiérrez et al. 2008; Ahn et al. 2010; Wolfe 2013). Removal of exon 9 in the PS1-ΔE9
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mutation allows access to the catalytic site, resulting in the constitutively active form of the enzyme as
holoprotein, without the need for the cleavage process (Knappenberger et al. 2004). Accordingly, we
found higher levels of active fragment in SAMP8 and SHAP(−) mice than in mice supporting the
mutation, at early ages. However, levels of 18 kDa PS1 normalized with age. In contrast, holoprotein
PS1 levels were similar in all experimental groups up to the age of 9 months but were found
significantly increased in SHAP(+) at 12 months of age in comparison with APP/PS1, in agreement
with higher Aβ deposition in these mice at the same age. The greater participation of PS1 in amyloid
pathology, described in APP/PS1 and in SHAP(+), would be of importance when new drugs are studied
for AD treatment, and that it will be more interesting to focus on PS1 inhibitors rather than on BACE
inhibitors (Gandy and DeKosky 2013).
Increases in tau hyperphosphorylation also participate in exacerbating plaque formation; thus, the
presence of higher hyperphosphorylation processes could be the cause of the increase in amyloid
pathology (Guo et al. 2013). Therefore, to determine a possible link between amyloidosis and tau
pathology in SHAP(+) mice, we studied tau phosphorylation in several characteristic serine and tyrosine
epitopes in these mice in comparison with SAMP8 and APP/PS1. As described elsewhere, both SAMP8
and APP/PS1 possess an alteration in the tau phosphorylation process (Canudas et al. 2005; Aso et al.
2012). Total tau content was raised in APP/PS1 in comparison with that of SAMP8, whereas in
SHAP(+) levels, tau content was nearer to that of the senescence model (data not shown). Four different
phosphorylated epitopes were studied here. No changes were found and there is no clear correlation
between phosphorylation levels and the mouse strain at early and medium age. At 12 months, the oldest
age studied, APP/PS1 and SHAP(+) exhibited higher phosphorylation in Tau Ser199, Tau Ser396, and
Tau Ser404. Moreover, the data showed no specific correlation between tau and amyloid pathology up
to 12 months, where amyloid pathology was well established, as our results and the broad bibliography
published on APP/PS1 or in SAMP8 demonstrate (Lok et al. 2013a, b).
The lack of difference in phosphorylated tau epitope patterns studied in early ages among the strains is
in agreement with the no differential activation of tau kinases CDK5 and GSK3β until 9 months, at least
in SHAP(+). Instead, at 9 and at 12 months, SHAP(+) displayed an altered kinase pattern that correlates
with tau hyperphosphorylation, which shows higher phosphorylation levels in Ser199 and Ser404
epitopes. This fact is in agreement with the literature, which describes tau as a substrate for CDK5 and
GSK3β (Iqbal and Grundke-Iqbal 2008; Casadesús et al. 2012). In turn, this pattern also correlates with
the overexpression of CDK5 and p25, which results in increased tau phosphorylation at specific sites
(Currais et al. 2013). JNK has been implicated in tau phosphorylation in APP/PS1 and SAMP8 mice
(Díaz-Moreno et al. 2013). Levels of JNK are also increased in SHAP(+) at 12 months of age in
comparison with SAMP8 or APP/PS1.
OS is a well-established pathogenic factor in AD, and the association of OS with amyloid and tau
abnormalities is well known (Mondragón-Rodríguez et al. 2013). A redox imbalance has been described
in both SAMP8 and APP/PS1. The newly generated mice, SHAP(+), did not differ in protein levels
related with homeostatic control of OS, synch as catalase, superoxide dismutase (SOD), or nitric oxide
(NO) synthase. On the other hand, immunohistochemical studies showed that microgliosis and
astrogliosis were detectable in APP/PS1 and SHAP(+) in the hippocampus and cortex, indicating that
the OS described for APP/PS1 was present also in the SHAP(+). In reference to astrogliosis, and as
expected, reactive astroglia are localized near the plaques both in APP/PS1 and SHAP(+), indicating
that OS and a harmful effect occur mainly surrounding amyloid aggregation.
Conclusion
In conclusion, overexpression of APP and PS1 in a senescence background of SAMP8 generates a
model of AD linked with senescence, with exacerbation of the amyloidogenic process at late ages, and
maintains some of the histopathological hallmarks present in AD and also learning and memory
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